Autism: Biomedical complementary treatment approaches

Child and Adolescent Psychiatric Clinics of North America

Volumn 22, Issue 3, 2013, Pages 443-456

  Hendren, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism; Biomedical treatment; Complementary and alternative treatment; Integrative treatment

Indexed keywords

ACETYLCYSTEINE; ARIPIPRAZOLE; DOCOSAHEXAENOIC ACID; EDETIC ACID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN; MECOBALAMIN; MELATONIN; MEMANTINE; MULTIVITAMIN; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PANCREAS ENZYME; PLACEBO; PROBIOTIC AGENT; RISPERIDONE; SUCCIMER; TRACE ELEMENT;

ALTERNATIVE MEDICINE; AUTISM; CHELATION THERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPIGENETICS; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNOTHERAPY; IRRITABILITY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP TIME; UNSPECIFIED SIDE EFFECT;

ACETYLCYSTEINE; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHELATION THERAPY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMPLEMENTARY THERAPIES; EXCITATORY AMINO ACID ANTAGONISTS; FATTY ACIDS, OMEGA-3; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MELATONIN; MEMANTINE; MICRONUTRIENTS; TREATMENT OUTCOME; VITAMIN B 12;

EID: 84879605699     PISSN: 10564993     EISSN: 15580490     Source Type: Journal    
DOI: 10.1016/j.chc.2013.03.002     Document Type: Review

References (55)

1. Birdee G.S., Phillips R.S., Davis R.B., et al. Factors associated with pediatric use of complementary and alternative medicine. Pediatrics 2010, 125(2):249-256.
2. Wong H.H., Smith R.G. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. JAutism Dev Disord 2006, 36(7):901-909.
3. Hanson E., Kalish L.A., Bunce E., et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. JAutism Dev Disord 2007, 37(4):628-636.
4. Ben-Arye E., Frenkel M., Klein A., et al. Attitudes toward integration of complementary and alternative medicine in primary care: perspectives of patients, physicians and complementary practitioners. Patient Educ Couns 2008, 70(3):395-402.
5. Hallmayer J., Cleveland S., Torres A., et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011, 68(11):1095-1102.
6. Sanders S.J., Murtha M.T., Gupta A.R., et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 2012, 485(7397):237-241.
7. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003, 33(Suppl):245-254.
8. Saresella M., Marventano I., Guerini F.R., et al. An autistic endophenotype results in complex immune dysfunction in healthy siblings of autistic children. Biol Psychiatry 2009, 66(10):978-984.
9. Rutten B.P., Mill J. Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull 2009, 35(6):1045-1056.
10. Goines P., Van de Water J. The immune system's role in the biology of autism. Curr Opin Neurol 2010, 23(2):111-117.
11. James S.J., Melnyk S., Fuchs G., et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr 2009, 89(1):425-430.
12. Frye R.E., Rossignol D.A. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 2011, 69(5 Pt 2):41R-47R.
13. Bell J.G., Miller D., MacDonald D.J., et al. The fatty acid compositions of erythrocyte and plasma polar lipids in children with autism, developmental delay or typically developing controls and the effect of fish oil intake. Br J Nutr 2010, 103(8):1160-1167.
14. Rubenstein J.L. Three hypotheses for developmental defects that may underlie some forms of autism spectrum disorder. Curr Opin Neurol 2010, 23(2):118-123.
15. Harony H., Wagner S. The contribution of oxytocin and vasopressin to mammalian social behavior: potential role in autism spectrum disorder. Neurosignals 2010, 18(2):82-97.
16. Bent S., Hendren R.L. Improving the prediction of response to therapy in autism. Neurotherapeutics 2010, 7(3):232-240.
17. Hendren R.L., Bertoglio K., Ashwood P., et al. Mechanistic biomarkers for autism treatment. Med Hypotheses 2009, 73(6):950-954.
18. Levy S.E., Hyman S.L. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005, 11(2):131-142.
19. Hyman S.L., Levy S.E. Introduction: novel therapies in developmental disabilities-hope, reason, and evidence. Ment Retard Dev Disabil Res Rev 2005, 11(2):107-109.
20. Levy S.E., Hyman S.L. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008, 17(4):803-820. ix.
21. Hoffmann T.J., Kvale M.N., Hesselson S.E., et al. Next generation genome-wide association tool: design and coverage of a high-throughput European-optimized SNP array. Genomics 2011, 98(2):79-89. PMID:21565264 PMCID: PMC23146553.
22. McPheeters M.L., Warren Z., Sathe N., et al. Asystematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011, 127(5):e1312-e1321.
23. Narayanan A., White C.A., Saklayen S., et al. Effect of propranolol on functional connectivity in autism spectrum disorder-a pilot study. Brain Imaging Behav 2010, 4(2):189-197.
24. King B.H., Wright D.M., Handen B.L., et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. JAm Acad Child Adolesc Psychiatry 2001, 40(6):658-665.
25. Posey D.J., Kem D.L., Swiezy N.B., et al. Apilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004, 161(11):2115-2117.
26. Chez M.G., Aimonovitch M., Buchanan T., et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. JChild Neurol 2004, 19(3):165-169.
27. Deutsch S.I., Urbano M.R., Neumann S.A., et al. Cholinergic abnormalities in autism: is there a rationale for selective nicotinic agonist interventions?. Clin Neuropharmacol 2010, 33(3):114-120.
28. Chez M.G., Burton Q., Dowling T., et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. JChild Neurol 2007, 22(5):574-579.
29. Brown N., Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 2009, 72(3):333-337.
30. Doyle C.A., McDougle C.J. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother 2012, 13(11):1615-1629.
31. Lofthouse N., Hendren R., Hurt E., et al. A review of complementary and alternative treatments for autism spectrum disorders. Autism Res Treat 2012, 2012:870391. 10.1155/2012/870391.
32. Rossignol D.A. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009, 21(4):213-236.
33. Miano S., Ferri R. Epidemiology and management of insomnia in children with autistic spectrum disorders. Paediatr Drugs 2010, 12(2):75-84.
34. Wirojanan J., Jacquemont S., Diaz R., et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile Xsyndrome. JClin Sleep Med 2009, 5(2):145-150.
35. Rossignol D.A., Frye R.E. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011, 53(9):783-792.
36. Freeman M.P., Hibbeln J.R., Wisner K.L., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. JClin Psychiatry 2006, 67(12):1954-1967.
37. Bell J.G., MacKinlay E.E., Dick J.R., et al. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids 2004, 71(4):201-204.
38. Meguid N.A., Atta H.M., Gouda A.S., et al. Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem 2008, 41(13):1044-1048.
39. Vancassel S., Durand G., Barthelemy C., et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 2001, 65(1):1-7.
40. Meiri G., Bichovsky Y., Belmaker R.H. Omega 3 fatty acid treatment in autism. JChild Adolesc Psychopharmacol 2009, 19(4):449-451.
41. Johnson C.R., Handen B.L., ZImmer M., et al. Polyunsaturated fatty acid supplementation in young children with autism. JDev Phys Disabil 2010, 22(1):1-10.
42. Amminger G.P., Berger G.E., Schafer M.R., et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007, 61(4):551-553.
43. Bent S., Bertoglio K., Ashwood P., et al. Apilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. JAutism Dev Disord 2011, 41(5):545-554.
44. Bloch M.H., Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. JAm Acad Child Adolesc Psychiatry 2011, 50(10):991-1000.
45. Gillies D., Sinn J., Lad S.S., et al. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2012, (7). CD007986.
46. Bertoglio K., Jill James S., Deprey L., et al. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. JAltern Complement Med 2010, 16(5):555-560.
47. Hardan A.Y., Fung L.K., Libove R.A., et al. Arandomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012, 71(11):956-961. PMID:22342106.
48. Adams J.B., Audhya T., McDonough-Means S., et al. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr 2011, 11:111.
49. Munasinghe S.A., Oliff C., Finn J., et al. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial. JAutism Dev Disord 2010, 40(9):1131-1138.
50. Adams J.B., Audhya T., McDonough-Means S., et al. Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutr Metab (Lond) 2011, 8(1):34.
51. Mehl-Madrona L., Leung B., Kennedy C., et al. Micronutrients versus standard medication management in autism: a naturalistic case-control study. J Child Adolesc Psychopharmacol 2010, 20(2):95-103.
52. Adams J.B., Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. JAltern Complement Med 2004, 10(6):1033-1039.
53. Gupta S. Treatment of children with autism with intravenous immunoglobulin. JChild Neurol 1999, 14(3):203-205.
54. Adams J.B., Baral M., Geis E., et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A-medical results. BMC Clin Pharmacol 2009, 9:16.
55. Adams J.B., Baral M., Geis E., et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results. BMC Clin Pharmacol 2009, 9:17.